Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

Fig. 3

Solicited injection-site adverse events (a) and general adverse events (b) in adults aged 18–49 years in the total vaccinated cohort. IIV4-I, quadrivalent inactivated influenza vaccine manufacturing by investigational process; IIV4, licenced quadrivalent inactivated influenza vaccine; CI, confidence interval; GI, gastrointestinal; N, number of subjects in the in the total vaccinated cohort who returned diary cards

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us